Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test

MT Newswires Live06-14

Renalytix (RNLX) said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier.

As of Aug. 1, the test will be covered by Medicare for patients with diagnosed type 2 diabetes and stage 1-3b chronic kidney disease as "reasonable and necessary," the company said.

The Medicare coverage of KidneyintelX.dkd, which will cost $950 per test, will "prompt additional major coverage decisions" and support expedited testing adoption, Renalytix CEO James McCullough said.

Renalytix shares were up more than 10% in recent Friday premarket activity.

Price: 0.5200, Change: +0.05, Percent Change: +10.90

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2443212176?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-14 20:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2443212176","market":"us","top_or_hot":-1,"title":"Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test","media":"MT Newswires Live","content":"<html><body><p> Renalytix (RNLX) said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier. </p><p>As of Aug. 1, the test will be covered by Medicare for patients with diagnosed type 2 diabetes and stage 1-3b chronic kidney disease as \"reasonable and necessary,\" the company said.</p><p>The Medicare coverage of KidneyintelX.dkd, which will cost $950 per test, will \"prompt additional major coverage decisions\" and support expedited testing adoption, Renalytix CEO James McCullough said.</p><p>Renalytix shares were up more than 10% in recent Friday premarket activity.</p><p>Price: 0.5200, Change: +0.05, Percent Change: +10.90</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Renalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRenalytix Secures Medicare's Final Local Coverage Determination for Kidney Disease Test\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-14 20:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Renalytix (RNLX) said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier. As of Aug. 1, the test will be covered by Medicare for patients with...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4167","symbol_name":"医疗保健技术","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2443212176","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2443212176","pubTimestamp":1718367766,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Renalytix  said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier. As of Aug. 1, the test will be covered by Medicare for patients with diagnosed type 2 diabetes and stage 1-3b chronic kidney disease as \"reasonable and necessary,\" the company said.The Medicare coverage of KidneyintelX.dkd, which will cost $950 per test, will \"prompt additional major coverage decisions\" and support expedited testing adoption, Renalytix CEO James McCullough said.Renalytix shares were up more than 10% in recent Friday premarket activity.Price: 0.5200, Change: +0.05, Percent Change: +10.90","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4167":"医疗保健技术","RNLX":"Renalytix AI plc"},"translate_title":"Renalytix确保Medicare最终确定肾脏疾病测试的本地承保范围","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RNLX":0.9},"content_text":"Renalytix (RNLX) said Friday that Medicare issued a final Local Coverage Determination for its kidneyintelX.dkd test a day earlier. As of Aug. 1, the test will be covered by Medicare for patients with diagnosed type 2 diabetes and stage 1-3b chronic kidney disease as \"reasonable and necessary,\" the company said.The Medicare coverage of KidneyintelX.dkd, which will cost $950 per test, will \"prompt additional major coverage decisions\" and support expedited testing adoption, Renalytix CEO James McCullough said.Renalytix shares were up more than 10% in recent Friday premarket activity.Price: 0.5200, Change: +0.05, Percent Change: +10.90","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2443212176"}